London, UK (PRWEB) April 23, 2014
Evaluation agreements enable a partner to the deal to gain rights to a technology or compound, subject to a span of time to evaluate the scope, applicability and quality of the technology to its desired endpoint. Typically, the technology is in the initial stage and/or unproven and the prospective partnering company strives to evaluate the technology within the scope of the due diligence process before signing a long-term license agreement. Evaluation agreements have always been a mainstream of technology licensing since the earliest times.
Meantime, an option agreement is distinctive in that the option is often an integral part of an agreement already entered by the prospective parties, providing the party with the option right to retain or extend certain rights to the technology already partnered. Option agreements gain more popularity as they offer additional flexibility within a deal for additional rights that the partners do not want to commit at the origin of the agreement.
New research study “Option and Evaluation Partnering Terms and Agreements in Pharma, Biotech and Diagnostics” worked out by CurrentPartnering is now available at MarketPublishers.com
Title: Option and Evaluation Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
Published: April, 2014
Price: US$ 2,995.00
The topical study provides a comprehensive understanding of, and access to the option and evaluation partnering agreements entered into by the global dominant biopharma companies. It offers in-depth insights into the negotiation process, contains an extensive summary of key information on the deals and agreements’ structure, terms, payment clauses, contract documents, etc. The research report includes a detailed listing of all evaluation and option deals during 2009-2013, provides links to the on-line copies of these agreements, touches upon the most significant issues concerning partnering deals in the biopharma market, and also encloses a slew of figures and tables, illustrating the activities and trends in option and evaluation dealmaking during 2009-2013. Besides, the topical report fixes up prospective dealmakers with everything they need to know about evaluation and option alliances.
Reasons to Buy:
- Expand knowledge about the major deals and agreements in the world biopharma market during 2009-2013.
- Gain a comprehensive understanding of why and how the top enterprises enter evaluation and option deals.
- Get a clear idea of the flexibility of a prospective partner’s negotiated deals terms.
- Gain in-depth insights into the negotiation process.
- Learn about the most important deals terms and important aspects.
- Achieve access to valuable contract documents.
- Learn how to derive maximum benefits and value from a deal and take informed business decisions.
More in-demand research studies by the publisher can be found at CurrentPartnering page.